Stay updated with breaking news from Nasdaq Cue. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Cue Biopharma, Inc. (NASDAQ:CUE – Get Free Report) saw a large increase in short interest during the month of April. As of April 15th, there was short interest totalling 4,780,000 shares, an increase of 13.8% from the March 31st total of 4,200,000 shares. Based on an average trading volume of 256,300 shares, the short-interest ratio […]
Cue Biopharma (NASDAQ:CUE – Get Free Report)‘s stock had its “outperform” rating restated by stock analysts at Oppenheimer in a note issued to investors on Tuesday, Benzinga reports. They currently have a $10.00 target price on the stock. Oppenheimer’s target price suggests a potential upside of 390.20% from the company’s current price. Several other research […]
Cue Biopharma, Inc. (NASDAQ:CUE – Get Free Report) saw a significant growth in short interest during the month of January. As of January 15th, there was short interest totalling 3,650,000 shares, a growth of 6.7% from the December 31st total of 3,420,000 shares. Based on an average daily volume of 361,500 shares, the short-interest ratio […]
BOSTON, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...
Prosight Management LP lessened its holdings in Cue Biopharma, Inc. (NASDAQ:CUE – Free Report) by 37.4% during the first quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,151,855 shares of the company’s stock after selling 688,655 shares during the quarter. Cue Biopharma comprises 1.9% of Prosight Management […]